Equities research analysts forecast that Horizon Pharma PLC (NASDAQ:HZNP) will post $267.58 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Horizon Pharma’s earnings. The highest sales estimate is $268.91 million and the lowest is $266.25 million. Horizon Pharma posted sales of $310.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The company is scheduled to issue its next quarterly earnings results on Monday, February 26th.
On average, analysts expect that Horizon Pharma will report full-year sales of $267.58 million for the current year. For the next year, analysts expect that the company will post sales of $1.13 billion per share, with estimates ranging from $1.12 billion to $1.15 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.04. The business had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company’s revenue for the quarter was up 30.1% on a year-over-year basis. During the same period last year, the company earned $0.70 EPS.
Shares of Horizon Pharma (NASDAQ HZNP) opened at $14.86 on Thursday. The stock has a market capitalization of $2,410.00, a P/E ratio of 10.79, a PEG ratio of 1.26 and a beta of 1.31. Horizon Pharma has a one year low of $9.45 and a one year high of $18.31. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89.
Several hedge funds and other institutional investors have recently modified their holdings of HZNP. Paulson & CO. Inc. purchased a new position in Horizon Pharma during the 2nd quarter worth $58,584,000. Dimensional Fund Advisors LP increased its holdings in Horizon Pharma by 119.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after purchasing an additional 3,409,411 shares during the period. William Blair Investment Management LLC purchased a new position in Horizon Pharma during the 2nd quarter worth $23,557,000. Ameriprise Financial Inc. increased its holdings in Horizon Pharma by 419.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock worth $26,979,000 after purchasing an additional 1,717,841 shares during the period. Finally, Balyasny Asset Management LLC purchased a new position in Horizon Pharma during the 2nd quarter worth $13,958,000. Hedge funds and other institutional investors own 86.58% of the company’s stock.
WARNING: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/12/21/zacks-analysts-anticipate-horizon-pharma-plc-hznp-will-announce-quarterly-sales-of-267-58-million.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.